Allergy Safety Events in Health Care: Development and Application of a Classification Schema Based on Retrospective Review.


Journal

The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220

Informations de publication

Date de publication:
07 2022
Historique:
received: 02 12 2021
revised: 10 03 2022
accepted: 27 03 2022
pubmed: 11 4 2022
medline: 14 7 2022
entrez: 10 4 2022
Statut: ppublish

Résumé

Allergy safety requires understanding the operational processes that expose patients to their known allergens, including how and when such processes fail. To improve health care safety for patients with allergies, we developed and assessed an allergy safety event classification schema to describe failures resulting in allergy-related safety events. Using keyword searches followed by expert manual review of 299,031 voluntarily-filed safety event reports at 2 large academic medical centers, we identified and classified allergy-related safety events from 5 years of safety reports. We used driver diagrams to elucidate root causes for commonly observed allergy safety events in health care settings. From 299,031 safety reports, 1922 (0.6%) were extracted with keywords and 744 (0.2%) were manually confirmed as allergy-related safety events. Safety failures were due to incomplete/inaccurate electronic health record documentation (n = 375, 50.4%), human factors (n = 175, 23.5%), allergy alert limitation and/or malfunction (n = 127, 17.1%), data exchange and interoperability failures (n = 92, 12.4%), and electronic health record system default options (n = 30, 4.0%). Safety failures resulted in known allergen exposures to drugs (n = 537), including heparin (n = 27) and topical anesthetics such as lidocaine (n = 8); latex (n = 114); food allergens (n = 73); and adhesive (n = 23). We identified 744 allergy-related safety events to inform a novel safety failure classification schema as an important step toward a safer health care environment for patients with allergies. Improved systems are required to address safety issues with certain food and drug allergens.

Sections du résumé

BACKGROUND
Allergy safety requires understanding the operational processes that expose patients to their known allergens, including how and when such processes fail.
OBJECTIVE
To improve health care safety for patients with allergies, we developed and assessed an allergy safety event classification schema to describe failures resulting in allergy-related safety events.
METHODS
Using keyword searches followed by expert manual review of 299,031 voluntarily-filed safety event reports at 2 large academic medical centers, we identified and classified allergy-related safety events from 5 years of safety reports. We used driver diagrams to elucidate root causes for commonly observed allergy safety events in health care settings.
RESULTS
From 299,031 safety reports, 1922 (0.6%) were extracted with keywords and 744 (0.2%) were manually confirmed as allergy-related safety events. Safety failures were due to incomplete/inaccurate electronic health record documentation (n = 375, 50.4%), human factors (n = 175, 23.5%), allergy alert limitation and/or malfunction (n = 127, 17.1%), data exchange and interoperability failures (n = 92, 12.4%), and electronic health record system default options (n = 30, 4.0%). Safety failures resulted in known allergen exposures to drugs (n = 537), including heparin (n = 27) and topical anesthetics such as lidocaine (n = 8); latex (n = 114); food allergens (n = 73); and adhesive (n = 23).
CONCLUSIONS
We identified 744 allergy-related safety events to inform a novel safety failure classification schema as an important step toward a safer health care environment for patients with allergies. Improved systems are required to address safety issues with certain food and drug allergens.

Identifiants

pubmed: 35398557
pii: S2213-2198(22)00338-5
doi: 10.1016/j.jaip.2022.03.026
pmc: PMC9371622
mid: NIHMS1823771
pii:
doi:

Substances chimiques

Allergens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1844-1855.e3

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI150295
Pays : United States
Organisme : AHRQ HHS
ID : R01 HS022728
Pays : United States
Organisme : AHRQ HHS
ID : R01 HS025375
Pays : United States

Informations de copyright

Copyright © 2022 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Références

JAMA Netw Open. 2019 Jan 4;2(1):e185630
pubmed: 30646188
J Am Med Inform Assoc. 2020 Jun 1;27(6):917-923
pubmed: 32417930
J Patient Saf. 2022 Jan 1;18(1):e108-e114
pubmed: 32487880
J Am Med Inform Assoc. 1999 Jul-Aug;6(4):313-21
pubmed: 10428004
Ann Intern Med. 2012 Jul 3;157(1):29-43
pubmed: 22751758
Proc AMIA Symp. 2000;:2-6
pubmed: 11080034
BMC Health Serv Res. 2005 Nov 09;5:71
pubmed: 16280077
J Gen Intern Med. 2021 Jun;36(6):1814-1817
pubmed: 32959347
JAMA. 2018 Mar 27;319(12):1276-1278
pubmed: 29584833
Jt Comm J Qual Improv. 2001 Oct;27(10):509-21
pubmed: 11593885
JAMA. 1998 Oct 21;280(15):1311-6
pubmed: 9794308
J Am Med Inform Assoc. 2016 May;23(3):601-8
pubmed: 26578227
JAMA. 1997 Jan 22-29;277(4):307-11
pubmed: 9002493
Int J Qual Health Care. 2009 Feb;21(1):2-8
pubmed: 19147595
Br J Clin Pharmacol. 2011 May;71(5):684-700
pubmed: 21480948
J Am Med Inform Assoc. 2004 Nov-Dec;11(6):482-91
pubmed: 15298998
BMJ Qual Saf. 2014 Aug;23(8):670-7
pubmed: 24764136
J Allergy Clin Immunol. 2018 Jan;141(1):41-58
pubmed: 29157945
Allergy. 2016 Sep;71(9):1305-13
pubmed: 26970431
Qual Health Res. 2017 Mar;27(4):591-608
pubmed: 27670770
J Patient Saf. 2021 Dec 1;17(8):e1595-e1604
pubmed: 30720546
JAMA Netw Open. 2020 Nov 2;3(11):e2022836
pubmed: 33196805
Stud Health Technol Inform. 2010;153:23-46
pubmed: 20543237

Auteurs

Neelam A Phadke (NA)

Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass; Massachusetts General Physicians Organization, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass; Edward P. Lawrence Center for Quality and Safety, Massachusetts General Hospital and Massachusetts General Physicians Organization, Boston, Mass. Electronic address: nphadke@partners.org.

Paige Wickner (P)

Harvard Medical School, Boston, Mass; Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Boston, Mass.

Liqin Wang (L)

Harvard Medical School, Boston, Mass; Division of General Internal Medicine, Department of Medicine, Brigham & Women's Hospital, Boston, Mass.

Li Zhou (L)

Harvard Medical School, Boston, Mass; Division of General Internal Medicine, Department of Medicine, Brigham & Women's Hospital, Boston, Mass.

Elizabeth Mort (E)

Harvard Medical School, Boston, Mass; Edward P. Lawrence Center for Quality and Safety, Massachusetts General Hospital and Massachusetts General Physicians Organization, Boston, Mass; Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Mass; Department of Health Care Policy, Harvard Medical School, Boston, Mass.

David W Bates (DW)

Harvard Medical School, Boston, Mass; Division of General Internal Medicine, Department of Medicine, Brigham & Women's Hospital, Boston, Mass; Harvard T.H. Chan School of Public Health, Boston, Mass.

Claire Seguin (C)

Martha's Vineyard Hospital, Oak Bluffs, Mass.

Xiaoqing Fu (X)

Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass; The Mongan Institute, Massachusetts General Hospital, Boston, Mass.

Kimberly G Blumenthal (KG)

Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass; Edward P. Lawrence Center for Quality and Safety, Massachusetts General Hospital and Massachusetts General Physicians Organization, Boston, Mass; The Mongan Institute, Massachusetts General Hospital, Boston, Mass.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH